secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2026-07-17T20:20:39+00:00
Accession:  0001867096-26-000055
Event type: debt
Sentiment:  neutral
Materiality: 0.55
Item codes: 3.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris retires $33.5M of 2028 convertible notes via exchange and conversion
--------------------------------------------------------------------------

- Exchanged ~$23M principal of 8.00% Convertible Senior Notes due 2028 for ~5.0M shares and ~$23M cash.
- Separately, a holder converted $10.5M principal into ~3.6M shares.
- After transactions, no 2028 Notes remain outstanding; all cancelled.
- Shares issued in exchange were unregistered, relying on Section 4(a)(2) exemption; conversion shares on Section 3(a)(9).
- Company funded cash portion with liquidity on-hand.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709626000055/0001867096-26-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709626000055/xers-20260715.htm
  HTML page:      https://secwatch.observer/filing/0001867096-26-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer